Ignite Creation Date:
2025-12-24 @ 4:08 PM
Ignite Modification Date:
2026-01-11 @ 8:28 AM
Study NCT ID:
NCT00645866
Status:
COMPLETED
Last Update Posted:
2011-05-16
First Post:
2008-03-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Sponsor:
Mayo Clinic
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CDR0000582618
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Julian R. Molina, M.D., Ph.D.
Old Organization:
Mayo Clinic Cancer Center
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |